#USA #Fremont #Ultima Genomics #Oncology Solutions #Elena Helman

Ultima Genomics Appoints Elena Helman as VP of Oncology Solutions

Ultima Genomics has recently made a significant leadership appointment aimed at enhancing their oncology sector. The company, renowned for its cutting-edge sequencing technology, has welcomed Dr. Elena Helman as the new Vice President of Oncology Solutions. In this pivotal role, Helman will focus on steering the company's oncology solutions strategy while bringing her extensive experience in cancer genomics, clinical diagnostics, and bioinformatics into play.

Elena Helman is no stranger to the complexities of oncology, boasting over 15 years of experience in cancer biology and data analytics. Her past roles include serving as the Vice President of Technology at Xilis, where she made considerable strides in the development of tumor-derived organoid models intended to expedite precision oncology and therapeutic ventures. This wealth of knowledge uniquely qualifies her to lead Ultima's efforts as the company aims to broaden its reach in the clinical oncology landscape.

Before her tenure at Xilis, Helman contributed immensely to clinical advancements at Guardant Health, where she was instrumental in fine-tuning clinical-grade circulating tumor DNA (ctDNA) assays. These assays play a crucial role in companion diagnostics and detecting minimal residual disease. Her collaborations with pharmaceutical giants complemented her endeavors, ensuring that innovative liquid biopsy technologies were seamlessly implemented within clinical and biopharma frameworks.

Gilad Almogy, Founder and CEO of Ultima Genomics, expressed great enthusiasm about Helman's appointment, stating, "Elena's depth of experience at the intersection of cancer biology, bioinformatics, and clinical diagnostics makes her an exceptional addition to the Ultima leadership team. Her expertise will be instrumental as we expand our solutions portfolio to support clinical oncology applications and enable scalable, cost-effective sequencing for cancer research and diagnostics."

Helman holds a PhD in Bioinformatics and Integrative Genomics from the esteemed Harvard–MIT Division of Health Sciences and Technology. During her doctoral research, she had the opportunity to work at both the Dana-Farber Cancer Institute and the Broad Institute, further solidifying her position as a leading expert in the field.

In her words, Helman expressed her excitement about joining the Ultima team during this transformative period for clinical oncology. "I'm thrilled to join Ultima Genomics at a time when sequencing economics and scale are becoming critical enablers for clinical oncology," she stated. "Ultima's technology has the potential to fundamentally change how genomic data is generated and applied in cancer diagnostics and drug development, and I look forward to helping extend that impact into the clinic."

In the coming months, Helman will be leading initiatives that aim to accelerate Ultima's foray into clinical oncology, ranging from translational research and biomarker identification to next-generation diagnostic solutions. The company's mission emphasizes harnessing the power of genomic information at an unprecedented scale. By overcoming the conventional barriers associated with sequencing, Ultima seeks to revolutionize how researchers and clinicians utilize genomic data to address complex biological challenges.

As the company embraces this new chapter, the addition of Dr. Helman to the leadership team stands as a strategic move to fortify its leadership in oncology and enrich its product offerings in the healthcare industry. Her commitment to advancing clinical applications for genomic technologies aligns seamlessly with Ultima Genomics' vision for the future of cancer diagnostics and treatments.

For further details about Ultima Genomics and its mission to redefine genomic information scales, visit their official website at www.ultimagenomics.com.